Literature DB >> 14703235

Losartan induced fetal toxicity.

Bonilla Nayar1, Ashwani Singhal, Rajiv Aggarwal, Neena Malhotra.   

Abstract

Losartan is a specific angiotensin II receptor antagonist. Although the teratogenic effects of angiotensin converting enzyme (ACE) inhibitors are well documented there are limited reports of losartan induced fetal toxicity. The authors report a case of incomplete ossification of skull bones, transient oliguria and feed intolerance in a newborn following in-utero exposure to losartan.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14703235     DOI： 10.1007/bf02730601

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  6 in total

1.  Angiotensin-II-receptor inhibitors in pregnancy.

Authors:  N A Chung; G Y Lip; M Beevers; D G Beevers
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

2.  Angiotensin-II-receptor inhibitors in pregnancy.

Authors:  A Hinsberger; A M Wingen; P F Hoyer
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

3.  Angiotensin-II-receptor inhibitors in pregnancy.

Authors:  M A Lambot; D Vermeylen; J C Noël
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

4.  Losartan and fetal toxic effects.

Authors:  H Saji; M Yamanaka; A Hagiwara; R Ijiri
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

Review 5.  [Teratogenic effects of ACE-inhibitors and angiotensin II receptor antagonists].

Authors:  A M Sørensen; S Christensen; T E Jonassen; D Andersen; J S Petersen
Journal:  Ugeskr Laeger       Date:  1998-03-02

6.  Effects of losartan on the cardiovascular system, renal haemodynamics and function and lung liquid flow in fetal sheep.

Authors:  K M Stevenson; K J Gibson; E R Lumbers
Journal:  Clin Exp Pharmacol Physiol       Date:  1996-02       Impact factor: 2.557
  6 in total
  5 in total

1.  Roles of the Angiotensin System in Neonatal Lung Injury and Disease.

Authors:  Chintan Gandhi; Bruce D Uhal
Journal:  JSM Atheroscler       Date:  2016-11-02

Review 2.  Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review.

Authors:  Chisa Shimada; Rina Akaishi; Kazutoshi Cho; Mamoru Morikawa; Yosuke Kaneshi; Takahiro Yamda; Hisanori Minakami
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

3.  Renal tubular dysgenesis and reversible hypocalvaria after intrauterine exposure to an angiotensin receptor blocker.

Authors:  Akio Yamada; Yoshikazu Tsuji; Yuich Kato; Norishi Ueda
Journal:  NDT Plus       Date:  2011-04

Review 4.  Safety perspectives on presently considered drugs for the treatment of COVID-19.

Authors:  Sophie L Penman; Robyn T Kiy; Rebecca L Jensen; Christopher Beoku-Betts; Ana Alfirevic; David Back; Saye H Khoo; Andrew Owen; Munir Pirmohamed; B Kevin Park; Xiaoli Meng; Christopher E Goldring; Amy E Chadwick
Journal:  Br J Pharmacol       Date:  2020-08-13       Impact factor: 8.739

5.  Prenatal hypocalvaria after prolonged intrauterine exposure to angiotensin II receptor antagonists.

Authors:  Marine Lallemant; Sarah Prévost; François Nobili; Didier Riethmuller; Rajeev Ramanah; Marie-France Seronde; Nicolas Mottet
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Oct-Dec       Impact factor: 1.636
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.